AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move ...

Appointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with ...